Meplazumab - Pacific Meinuoke Bio Pharmaceutical
Alternative Names: Anti-CD147 humanized meplazumab; humanized mAb against CD147; KetantinLatest Information Update: 30 Aug 2024
At a glance
- Originator Fourth Military Medical University
- Developer Fourth Military Medical University; Pacific Meinuoke Biopharmaceutical
- Class Antimalarials; Antivirals; Monoclonal antibodies
- Mechanism of Action Metalloprotease inhibitors; Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III COVID 2019 infections
- Phase II Coronary artery disease; Malaria
Most Recent Events
- 26 Aug 2024 Phase-II clinical trials in Coronary artery disease in China (IV) (NCT06572267)
- 28 May 2024 Preclinical development is ongoing China prior to April 2024 (NCT06040346)
- 26 Apr 2024 Phase-II clinical trials in Malaria in Kenya (IV) (NCT06040346)